BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, we have documented that the underlying mechanisms of matrine’s anti-CML activity were involved in the inhibition of MAPK/ERK signaling pathway and down-regulated expression of BCR/ABL.